MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Journal of Clinical Oncology
Topic
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

9,514 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
9,514 works in the cohort · of 4,299,418page 59 of 191

Labels cover 106 of 9,514 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 9,514 of 9,514 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affunlabeled
Higher dose per fraction and shorter overall treatment time using intensity-modulated radiation therapy versus conventional radiation therapy with concurrent carboplatin and 5-fluorouracil for locally advanced oropharyngeal carcinoma: A comparison of toxicity and efficacy
S. Clavel, David H. Nguyen, Philippe Després, B. Fortin, Geneviève Coulombe, David Donath +4 more
2009· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
7
citations
affunlabeled
Trial in progress: A phase 1, multicenter, open-label, dose-exploration and dose-expansion study evaluating the safety, tolerability, pharmacokinetics, and efficacy of AMG650 in subjects with advanced solid tumors.
Ramaswamy Govindan, Amanda Townsend, Kathy D. Miller, Inderjit Mehmi, Yasutoshi Kuboki, Ecaterina E. Dumbrava +9 more
2021· article· en· Journal of Clinical Oncology· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
7
citations
affunlabeled
A subgroup analysis of small lymphocytic and marginal zone lymphomas in the Eastern Cooperative Oncology Group protocol E4402 (RESORT): A randomized phase III study comparing two different rituximab dosing strategies for low tumor burden indolent non-Hodgkin lymphoma.
Michael E. Williams, Fangxin Hong, Brad S. Kahl, Randy D. Gascoyne, Lynne I. Wagner, John C. Krauss +1 more
2012· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
7
citations
affunlabeled
Metformin Active Surveillance Trial in Low-Risk Prostate Cancer
Neil Fleshner, Rui Bernardino, Jonathan I. Izawa, Darrel Drachenberg, Jeff Saranchuk, Adrian Fairey +28 more
2025· article· en· Journal of Clinical Oncology· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
7
citations
affaboutunlabeled
Randomized controlled trials (RCTs) examining continuous (CS) versus intermittent strategies (IS) of delivering systemic treatment (Tx) for untreated metastatic colorectal cancer (mCRC): A meta-analysis from the Cancer Care Ontario program in evidence-based care.
Scott R. Berry, Roxanne Cosby, Timothy R. Asmis, Kelvin Chan, Nazik Hammad, Monika K. Krzyzanowska
2013· article· en· Journal of Clinical Oncology· Economics, Econometrics and Finance
machine prediction:candidate · metaepi_broadconsensus · none
7
citations
affaboutunlabeled
Patient-reported outcomes from MA.17R: A randomized trial of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer.
Julie Lemieux, Paul E. Goss, Wendy R. Parulekar, James N. Ingle, Kathleen I. Pritchard, Nicholas J. Robert +7 more
2016· article· en· Journal of Clinical Oncology· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
7
citations

How this was built: Screen · Findings · About